Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population.

Abstract

AIMS TB is a serious global public health problem. Isoniazid, a key drug used to treat latent TB, can cause hepatotoxicity in some patients. This pilot study investigated the effects of genetic variation in NAT2 and CYP2E1 on isoniazid-induced hepatotoxicity in TB contacts in British Columbia, Canada. MATERIALS & METHODS DNA re-sequencing was used to… (More)
DOI: 10.2217/pgs.09.66

Topics

Cite this paper

@article{Yamada2009GeneticVO, title={Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population.}, author={So Yamada and Mila Tang and Kathryn J Richardson and Julius Halaschek-Wiener and Matthew Ming Ki Chan and Victoria J. Cook and Mohsen Sadatsafavi and R. Kevin Elwood and Angela Brooks-Wilson and Fawziah Marra}, journal={Pharmacogenomics}, year={2009}, volume={10 9}, pages={1433-45} }